http://www.alzheimerstreatments.com Alzheimers Treatments Fri, 07 Nov 2008 09:55:47 +0000 http://backend.userland.com/rss092 en Galantamine - What's Old with Acetylcholine is New to Us by Will Block All the jokes about "snail mail" notwithstanding, the postal service is an amazingly efficient enterprise that handles mountains of letters and packages (and junk) with such reliability that we seldom give a thought as to whether or not our ... http://www.alzheimerstreatments.com/article-galantamine-increases-acetylcholline Galantamine: Boost Memory and Keep It by Will Block In a recent issue of FEBS Letters (Federation of European Biochemical Societies), researchers at Israel's respected Weizmann Institute published an elucidation of the mechanism by which galantamine - a compound extracted from the common snowdrop (Galanthus nivalis) - blocks the action of a ... http://www.alzheimerstreatments.com/article-galantamine-has-benefits-over-aricept%c2%ae Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Department of Clinical Neurosciences, Helsinki University Central Hospital, Helsinki, Finland. timo.erkinjuntti@hus.fi ABSTRACT BACKGROUND: Vascular dementia is the second commonest form of dementia, and vascular factors contribute to ... http://www.alzheimerstreatments.com/galantamine-efficacy-of-galantamine-in-dementia-and-alzheimers-disease Galantamine for Alzheimer's disease. (Cochrane Review) Olin J, Schneider L Adult and Geriatric Treatment and Preventative Interventions Branch, National Institute of Mental Health, NIMH, Room 7160, MSC 9635, 6001 Executive Blvd., Bethesda, Maryland 20892-9635, USA. jolin@mail.nih.gov ABSTRACT BACKGROUND: Galantamine (also called galanthamine, marketed as Reminyl (Janssen)) was isolated from several plants, including daffodil bulbs, but is now synthesized. ... http://www.alzheimerstreatments.com/galantamine-for-alzheimers-disease Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease. Albuquerque EX, Santos MD, Alkondon M, Pereira EF, Maelicke A Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore MD 21201, USA. ealbuque@umaryland.edu Alzheimer Dis Assoc Disord 2001 Aug;15 Suppl 1:S19-25 ABSTRACT Impaired cholinergic function ... http://www.alzheimerstreatments.com/galantamine-novel-approach-to-the-treatment-of-alzheimer-disease Maintaining cognitive function in Alzheimer disease: how effective are current treatments? Tariot PN Department of Psychiatry, University of Rochester Medical Center New York, USA. Pierre_Tariot@URMC.Rochester.edu Alzheimer Dis Assoc Disord 2001 Aug;15 Suppl 1:S26-33 ABSTRACT Cognitive impairment, a core feature of Alzheimer disease (AD), is highly correlated with functional decline and caregiver time. Over 12 months, patients with mild-to-moderate ... http://www.alzheimerstreatments.com/galantamine-maintaining-cognitive-function-in-alzheimer-disease Maintaining functional and behavioral abilities in Alzheimer disease Winblad B Karolinska Institutet, Alzheimer Disease Research Center Huddinge Hospital, Sweden. bengt.winblad@neurotec.ki.se Alzheimer Dis Assoc Disord 2001 Aug;15 Suppl 1:S34-40 ABSTRACT Limitations associated with conventional acetylcholinesterase inhibitors have led to interest in therapies with more than one mode of action. Galantamine is a novel treatment for Alzheimer disease with a ... http://www.alzheimerstreatments.com/galantamine-maintaining-functional-abilities-in-alzheimer-disease Galantamine: a new Alzheimer drug with a past life Pearson VE Department of Pharmacy The Johns Hopkins Hospital Baltimore, MD, USA. vpearso@jhmi.edu Ann Pharmacother 2001 Nov;35(11):1406-13 ABSTRACT OBJECTIVE: To review the historic, pharmacologic, pharmacokinetic, therapeutic, and toxicologic features of galantamine, a new acetylcholinesterase inhibitor, and to assess its role in the treatment of Alzheimer disease symptoms. DATA SOURCES: ... http://www.alzheimerstreatments.com/galantamine-a-new-alzheimer-disease-drug-with-a-past-life The pharmacological rationale for treating vascular dementia with galantamine Maelicke, A Institute of Physiological Chemistry and Pathobiochemistry, Johannes Gutenberg University Medical School, Mainz, Germany. Int J Clin Pract Suppl 2001 May;(120):24-8 ABSTRACT There is considerable evidence indicating that, as in Alzheimer's disease, the central cholinergic system is impaired in vascular dementia (VaD). Using lessons learned from ... http://www.alzheimerstreatments.com/galantamine-treating-vascular-dementia-with-galantamine Pharmacokinetic rationale for switching from donepezil to galantamine. Maelicke, A Laboratory of Molecular Neurobiology, Johannes-Gutenberg University Medical School Mainz, Germany. alfred.maelicke@uni-mainz.de Clin Ther 2001;23 Suppl A:A8-12 Abstract Galantamine, the most recently approved acetylcholinesterase inhibitor (AChEI) for use in the United States, has allosteric modulating activity at nicotinic receptors and inhibits acetylcholinesterase. This dual mechanism of action may ... http://www.alzheimerstreatments.com/galantamine-rationale-for-switching-from-donepezil-to-galantamine